ad info

 Headline News brief
 daily almanac
 CNN networks
 CNN programs
 on-air transcripts
 news quiz

CNN Websites
 video on demand
 video archive
 audio on demand
 news email services
 free email accounts
 desktop headlines

 message boards




Pentagon: Drug may be linked to Gulf War Syndrome


Report says more study needed on anti-nerve gas drug

October 19, 1999
Web posted at: 3:02 p.m. EDT (1902 GMT)

In this story:

Future use of drug possible

Further study suggested


WASHINGTON (CNN) -- A drug given to U.S. troops during the Persian Gulf War to protect against a nerve gas may be linked to ailments now known as Gulf War Syndrome, the Pentagon said Tuesday, acknowledging what some medical researchers and veterans have long suspected.

The U.S. Military

A study of scientific literature about pyriostigmine bromide -- or PB -- found that the drug "cannot be ruled out" as the cause for an array of symptoms. They include chronic pain, digestive problems, nausea, skin rashes, fatigue, aching joints, memory loss and concentration problems suffered by thousands of veterans of the 1990-91 war.

Future use of drug possible

While Pentagon officials said they will still consider using the drug as an antidote for the nerve gas soman, military leaders "would be very judicious in deciding whether to use PB in the future," said Dr. Sue Bailey, assistant secretary of defense for health affairs.

"The decision would involve weighing concerns about possible long-term health effects with a threat-risk assessment of how likely it is that soman would be used against our troops," she said.

Earlier government studies had ruled out PB as a possible cause of Gulf War Syndrome but now, "we simply don't know," said the 385-page report's author, Dr. Beatrice Alexandra Golomb of Rand Corp., a California research institute.

The findings do not necessarily mean PB caused the symptoms, "only that the possibility cannot be dismissed," wrote Golomb, a physician at San Diego Veterans Affairs Medical Center.

Further study suggested

Golomb and Bailey were joined at a Pentagon news conference by Dr. Bernard Rostker, the undersecretary of the army who is the Pentagon's senior official overseeing Gulf War illnesses.

"This report is very helpful in framing the problem for future study," Bailey said. "Dr. Golomb and I agree that further research regarding these theories is clearly necessary."

According to the report, areas for further study include:

• Whether individual people react differently to PB

• Whether people who have a negative initial reaction are more likely to suffer negative long-term effects

• Whether stress can change the way the drug enters the brain

• Whether environmental factors in the Gulf caused the U.S. supply of PB to become toxic

• Whether PB was administered in proper dosages

• Whether a person's weight might be a factor to assure proper dosage

PB was given to about 250,000 of the nearly 700,000 American troops sent to the Persian Gulf as protection against soman, a lethal, fast-acting nerve agent produced by the former Soviet Union and believed at the time to have been part of Iraq's arsenal.

"There is no antidote without PB," said Bailey.

Of $133 million spent by the Pentagon researching Gulf War syndrome, it has earmarked about $20 million to specifically to study the effects of the drug.

Mission accomplished, U.N. disarmament team leaves Iraq
July 28, 1999
U.N. envoy says toxins left in Baghdad pose no threat
July 22, 1999
U.N. dismantling weapons inspectors' lab in Iraq
July 14, 1999
Conference examines Gulf War Syndrome
March 1, 1999

U.S. Department of Defense
San Francisco Veterans Affairs Medical Center
Gulf War Syndrome Chronology
Gulf War Veteran Resource Pages
The Organization for the Prohibition of Chemical Weapons Home Page
Browse GulfLINK Declassified Documents

Note: Pages will open in a new browser window
External sites are not endorsed by CNN Interactive.
Enter keyword(s)   go    help

Back to the top   © 2001 Cable News Network. All Rights Reserved.
Terms under which this service is provided to you.
Read our privacy guidelines.